Bimekizumab
Bimekizumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Moderate to Severe Plaque Psoriasis、Psoriatic Arthritis、Axial Spondyloarthritis、Hidradenitis Suppurativa。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
12 项
全球在招研究
3 项
已进入 III/IV 期
18 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- UCB Biopharma SRL
- Leiden University Medical Center
- Spyre Therapeutics, Inc.
- NYU Langone Health
- Adelphi Real World
- NHS Greater Glasgow and Clyde
- Centre Hospitalier Universitaire de Nice
- Taichung Veterans General Hospital
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Bulgaria、Czechia、德国、Poland、Slovakia、荷兰、加拿大、英国、中国、丹麦、法国
正在招募患者的 Bimekizumab 研究
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
I 期招募中美国BulgariaCzechia德国NCT07290036SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
不适用招募中荷兰NCT07021495A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
II 期招募中美国加拿大NCT07766005Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
II 期招募中美国NCT07138898Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
不适用招募中英国NCT07166315A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
III 期招募中美国加拿大中国CzechiaNCT07219420Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
不适用招募中英国NCT06786936Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
II 期招募中法国NCT06742333A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
IV 期招募中中国台湾NCT07149792PsoBest - The German Psoriasis Registry
不适用招募中德国NCT01848028A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
I 期招募中美国加拿大德国西班牙NCT06888193An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
III 期招募中加拿大法国德国PolandNCT06668181
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。